Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease

Joint Bone Spine

Volumn 78, Issue 3, 2011, Pages 306-308

  Saidenberg Kermanac'h, Nathalie ^a,b   Souabni, Leila ^b   Prendki, Virginie ^b   Prie, Dominique ^c   Boissier, Marie Christophe ^a,b  

^a UNIVERSITÉ PARIS 13   (France)

^b AVICENNE HOSPITAL   (France)

^c INSERM   (France)

Author keywords

FGF23; Hypophosphatemia; Osteomalacia; Tenofovir; Tubulopathy

Indexed keywords

ATAZANAVIR; EMTRICITABINE; FIBROBLAST GROWTH FACTOR 23; PHOPHONEUROS; PHOSPHATE; RALTEGRAVIR; TENOFOVIR; UNCLASSIFIED DRUG;

ADULT; AMINOACIDURIA; ARTICLE; BLOOD ANALYSIS; BONE DEMINERALIZATION; BONE DENSITY; BONE SCINTISCANNING; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FATIGUE; GLUCOSURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; HYPOPHOSPHATEMIC RICKETS; KIDNEY TUBULE ABSORPTION; LIMB WEAKNESS; MALE; METABOLIC ACIDOSIS; MUSCULOSKELETAL PAIN; NEUROFIBROMA; NEUROFIBROMATOSIS; PHOSPHATURIA; PROTEIN BLOOD LEVEL; PROTEINURIA; TUBULAR DYSFUNCTION; WALKING DIFFICULTY; WEIGHT REDUCTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADENINE; ADULT; ANTI-HIV AGENTS; DRUG SUBSTITUTION; FIBROBLAST GROWTH FACTORS; HUMANS; HYPOPHOSPHATEMIA; MALE; NEUROFIBROMATOSIS 1; OSTEOMALACIA; PHOSPHATES; PHOSPHONIC ACIDS; PYRROLIDINONES; TREATMENT OUTCOME;

EID: 79955526959     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.11.007     Document Type: Article

References (10)

1. Nabeshima Y. The discovery of alpha-Klotho and FGF23 unveiled new insight into calcium and phosphate homeostasis. Cell Mol Life Sci 2008, 65:3218-3230.
2. Gattineni J., Baum M. Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol 2009, 10:1273-1283.
3. Rodríguez-Nóvoa S., Labarga P., Soriano V., et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 2009, 48:108-116.
4. Breton G., Alexandre M., Duval X., et al. Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1. Scand J Infect Dis 2004, 36:527-578.
5. Perrot S., Aslangul E., Szwebel T., et al. Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient. J Clin Rheumatol 2009, 15:72-74.
6. Earle K.E., Seneviratne T., Shaker J., et al. Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res 2004, 19:714-721.
7. Gutiérrez O.M., Mannstadt M., Isakova T., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008, 359:640-642.
8. Hannan F.M., Athanasou N.A., Teh J., et al. Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1. Eur J Endocrinol 2008, 158:265-271.
9. Ben-Baruch D., Ziv Y., Sandbank J., et al. Oncogenic osteomalacia induced by schwannoma in a patient with neurofibromatosis. Eur J Surg Oncol 1994, 20:57-61.
10. Prié D., Urena Torres P., Friedlander G. Latest findings in phosphate homeostasis. Kidney Int 2009, 75:882-889.